Diligence memo · auto-generated · as of July 2, 2026
Sudo Biosciences, Inc.
Sudo Biosciences, Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Sudo Biosciences, Inc. operates in Biotech / Pharma, based in CARMEL.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Sudo Biosciences, Inc. has raised $73M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $64M on 2023-12-15.
Most recent recorded round closed around 2023-12-15.
Valuation (modeled)modeled
Provath models Sudo Biosciences, Inc. at approximately $686M (range $202M–$1.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.36× the median modeled value of Series C Biotech / Pharma companies in 2022–2024 (8 peers) — value vs value, same stage and era. Within the normal band (136% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 11 months.
Last raise 2.5 yr ago; this sector typically re-raises about every 15 months.
Slightly overdue versus sector cadence.
The last round stepped up 1.2× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 92% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 93% of those peers.
Closest niche peers: Sherlock Biosciences, Inc., Pacific Biosciences Of California, Inc., Elephas Biosciences Corp, NOLA PharmaHoldings, LLC, Belenos Biosciences, Inc..
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.